Shanghai Lanyi Therapeutics Co., Ltd.
3 clinical trials · Sponsor
◉ Watch Shanghai Lanyi Therapeutics Co., Ltd.
| Record | Firm | Date |
|---|---|---|
| A Phase I, Dose Escalation, Open-label, Multicenter Study of EA5 Injection in Adults With APS and Recurrent Thrombosis (NCT07632976) | Shanghai Lanyi Therapeutics Co., Ltd. | 2026-05-25 |
| A Phase Ib, Multicenter, Open-Label Study of Multiple-Dose EA5 in Adults With Paroxysmal Nocturnal Hemoglobinuria (PNH) (NCT07256301) | Shanghai Lanyi Therapeutics Co., Ltd. | 2024-01-03 |
| A Phase Ia Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Doses of EA5 in Healthy Adult Subjects (NCT07256288) | Shanghai Lanyi Therapeutics Co., Ltd. | 2023-05-31 |
Track Shanghai Lanyi Therapeutics Co., Ltd. automatically
Every clearance here is in the API, with alerts when new ones post.